Search results for " hepatocellular"

showing 10 items of 592 documents

Imaging findings of hepatic Focal Nodular Hyperplasia (FNH) in Gadoxetic Acid vs Gadobenate Dimeglumine-enhanced MR: preliminary results

2009

focal nodular hyperplasia hepatocellular-specific contrast agent
researchProduct

Imaging findings of hepatic focal nodular hyperplasia in Gd-EOB-DTPA vs Gd-BOPTA -enhanced MR: preliminary results.

2009

focal nodular hyperplasia hepatocellular-specific contrast agent
researchProduct

Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b

2021

HCV is an important cause of hepatocellular carcinoma (HCC). HCV NS5A domain-1 interacts with cellular proteins inducing pro-oncogenic pathways. Thus, we explore genetic variations in NS5A domain-1 and their association with HCC, by analyzing 188 NS5A sequences from HCV genotype-1b infected DAA-naïve cirrhotic patients: 34 with HCC and 154 without HCC. Specific NS5A mutations significantly correlate with HCC: S3T (8.8% vs. 1.3%, p = 0.01), T122M (8.8% vs. 0.0%, p &lt

hepatitis C virusLiver CirrhosisMaleCirrhosisvirusesHepacivirusViral Nonstructural ProteinsNS5Amedicine.disease_causeSeverity of Illness Indexgenetic variabilityMedicineLiver Neoplasmsvirus diseaseshepatocellular carcinomaMiddle AgedHepatitis CQR1-502Infectious DiseasesHepatocellular carcinomaHCVHost-Pathogen InteractionsFemaleDisease SusceptibilityCarcinoma HepatocellularGenotypeHepatitis C virusViremiaMicrobiologyArticleStructure-Activity RelationshipVirologyGenetic variationHumansGenetic variabilityNS5AneoplasmsAgedbusiness.industrycirrhosisSequence Analysis DNAbiochemical phenomena metabolism and nutritiongenotype 1bmedicine.diseaseSettore MED/17digestive system diseasesMutationCancer researchbusinessCarcinogenesisBiomarkersViruses
researchProduct

Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort

2017

We evaluated the cost-effectiveness of two alternative direct-acting antiviral (DAA) treatment policies in a real-life cohort of hepatitis C virus–infected patients: policy 1, “universal,” treat all patients, regardless of fibrosis stage; policy 2, treat only “prioritized” patients, delay treatment of the remaining patients until reaching stage F3. A liver disease progression Markov model, which used a lifetime horizon and health care system perspective, was applied to the PITER cohort (representative of Italian hepatitis C virus–infected patients in care). Specifically, 8,125 patients naive to DAA treatment, without clinical, sociodemographic, or insurance restrictions, were us…

hepatitis C virusPediatricsCost effectivenessViral HepatitisAdult; Aged; Aged 80 and over; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Health Policy; Hepatitis C; Humans; Middle Aged; Young Adult; Models Economic; HepatologyCost-Benefit AnalysisDirect-acting antiviralAdult; Aged; Aged 80 and over; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Health Policy; Hepatitis C; Humans; Middle Aged; Young Adult; Models EconomicCohort StudiesLiver disease0302 clinical medicineModelsHealth careantiviral therapy80 and overincremental cost-effectiveness ratiohealth care economics and organizationsHCV cost -effectivenessAged 80 and overDirect-acting antiviral hepatocellular carcinoma hepatitis C virus incremental cost-effectiveness ratio interferon quality-adjusted life-years sustained virological response willingness to payCost–benefit analysis030503 health policy & servicesquality-adjusted life-yearsHealth PolicyHepatitis Chepatocellular carcinomainterferonMiddle AgedHepatitis CModels EconomicAdult; Aged; Aged 80 and over; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Health Policy; Hepatitis C; Humans; Middle Aged; Young Adult; Models Economic; Hepatology; HCV; antiviral therapy; cost-effectiveness; real-life cohortCohortHCV030211 gastroenterology & hepatologyOriginal Articlesustained virological response0305 other medical scienceCohort studyHumanAdultmedicine.medical_specialtyEconomicAntiviral AgentsNO03 medical and health sciencesYoung Adultreal-life cohortmedicineHumansCost-Benefit Analysicost-effectivenessHealth policyAgedAntiviral AgentHepatologybusiness.industryOriginal Articlesmedicine.diseaseSurgeryCohort Studiebusinesswillingness to pay
researchProduct

CEUS LI-RADS: a pictorial review

2020

AbstractContrast-enhanced ultrasound (CEUS) greatly improved the diagnostic accuracy of US in the detection and characterization of focal liver lesions (FLLs), and it is suggested and often included in many international guidelines as an important diagnostic tool in the imaging work-up of cirrhotic patients at risk for developing hepatocellular carcinoma (HCC). In particular, CEUS Liver Imaging Reporting and Data System (LI-RADS) provides standardized terminology, interpretation, and reporting for the diagnosis of HCC. The aim of this pictorial essay is to illustrate CEUS features of nodules discovered at US in cirrhotic liver according to LI-RADS categorization.

lcsh:Medical physics. Medical radiology. Nuclear medicinemedicine.medical_specialtyCirrhotic liverCirrhosisHepatocellular carcinomalcsh:R895-920Diagnostic accuracy030218 nuclear medicine & medical imagingCholangiocarcinomaLiver tumor characterization03 medical and health sciences0302 clinical medicineContrast-enhanced ultrasonographyMedicineRadiology Nuclear Medicine and imagingEducational ReviewNeuroradiologyLiver imagingmedicine.diagnostic_testbusiness.industrySettore MED/37 - NeuroradiologiaInterventional radiologymedicine.diseaseStandardized terminologyCirrhosis030220 oncology & carcinogenesisHepatocellular carcinomaContrast-enhanced ultrasonography Hepatocellular carcinoma Cholangiocarcinoma Liver tumor characterization CirrhosisRadiologySettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessInsights into Imaging
researchProduct

Hazardous air pollutants and primary liver cancer in Texas.

2016

The incidence of hepatocellular carcinoma (HCC), the most common primary liver cancer, is increasing in the US and tripled during the past two decades. The reasons for such phenomenon remain poorly understood. Texas is among continental states with the highest incidence of liver cancer with an annual increment of 5.7%. Established risk factors for HCC include Hepatitis B and C (HBV, HCV) viral infection, alcohol, tobacco and suspected risk factors include obesity and diabetes. While distribution of these risk factors in the state of Texas is similar to the national data and homogeneous, the incidence of HCC in this state is exceptionally higher than the national average and appears to be di…

lcsh:Medicine010501 environmental sciences01 natural sciencesGeographical locations0302 clinical medicineRisk FactorsEpidemiology of cancerMedicine and Health SciencesMedicineOrganic Chemicalslcsh:Scienceeducation.field_of_studyAir PollutantsPrincipal Component AnalysisMultidisciplinaryOrganic CompoundsIncidence (epidemiology)IncidenceLiver DiseasesLiver NeoplasmsHepatitis BTexasPollutionChemistryOncology030220 oncology & carcinogenesisPhysical SciencesEngineering and TechnologyLiver cancerEnvironmental MonitoringResearch ArticlePollutantsCarcinoma HepatocellularEnvironmental EngineeringPopulationGastroenterology and HepatologyXylenesCarcinomas03 medical and health sciencesEnvironmental healthAir PollutionAromatic HydrocarbonsGastrointestinal TumorsHumansEnvironmental ChemistryRisk factoreducation0105 earth and related environmental sciencesbusiness.industrylcsh:REcology and Environmental SciencesOrganic ChemistryChemical CompoundsCancerCancers and NeoplasmsBenzeneEnvironmental ExposureHepatocellular Carcinomamedicine.diseaseUnited StatesHydrocarbonsCancer registryNorth Americalcsh:QHydrochloric AcidPeople and placesbusinessAcidsToluenePloS one
researchProduct

Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma.

2022

Worldwide, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) significantly increases mortality and morbidity. The Coronavirus Disease 2019 (COVID-19) outbreak has had a considerable impact on healthcare systems all around the world, having a significant effect on planned patient activity and established care pathways, in order to meet the difficult task of the global pandemic. Patients with hepatocellular carcinoma (HCC) are considered a particularly susceptible population and conceivably at increased risk for severe COVID-19 because of two combined risk factors: chronic advanced liver disease and HCC itself. In these challenging times, it is mandatory to reshape clinical pra…

liver cancerSettore MED/12 - GastroenterologiaSARS-CoV-2COVID-19; SARS-CoV-2; hepatocellular carcinoma; liver cancerCOVID-19hepatocellular carcinomaGeneral Medicineliver cancer.Journal of clinical medicine
researchProduct

Performance of Gd-BOPTA Magnetic Resonance in the diagnosis of Hepatocellular Carcinoma, compared to histology after orthotopic liver transplantation.

liver transplantation.Magnetic ResonanceHepatocellular CarcinomaGd-BOPTA; Magnetic Resonance; Hepatocellular Carcinoma; liver transplantation.Gd-BOPTA
researchProduct

Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib

2020

Sorafenib is the first multikinase inhibitor demonstrating a survival benefit for patients suffering from advanced hepatocellular carcinoma (HCC). However, 1 issue remains open: what is the factor able to predict which patients will be long survivors?In the present study, we harnessed the potential of conditional survival, aiming at estimating the probability that a patient receiving sorafenib survives for more than 3 years.The present multicentric study was conducted on a cohort of 438 HCC patients. The primary end point was conditional overall survival. Kaplan-Meier survival analysis was used to calculate conditional overall survival probabilities at 3 years.The 3-year conditional surviva…

macro-vascular portal vein invasionMaleCarcinoma HepatocellularAntineoplastic Agentsextra hepatic disease and BCLCsurvivalNLRAntineoplastic AgentCohort Studiesalpha-fetoproteinHumansLymphocyte CountSurvivorsprognostic factorAgedLiver NeoplasmsMiddle AgedSorafenibProgression-Free SurvivalItalyLiver Neoplasmalpha-fetoprotein; extra hepatic disease and BCLC; hepatitis C; macro-vascular portal vein invasion; NLR; prognostic factor; survivalFemaleCohort Studiehepatitis CCarcinoma Hepatocellular ...Liver Neoplasms ...Human
researchProduct

Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology.

2021

BACKGROUND & AIMS Hepatocellular carcinoma (HCC) is a common complication of chronic liver disease with diverse underlying aetiologies. REACH/REACH-2 were global phase III studies investigating ramucirumab in advanced HCC (aHCC) following sorafenib treatment. We performed an exploratory analysis of outcomes by liver disease aetiology and baseline serum viral load. METHODS Meta-analysis was conducted in patients with aHCC and alpha-fetoprotein (AFP) ≥400 ng/mL (N = 542) from REACH/REACH-2 trials. Individual patient-level data were pooled with results reported by aetiology subgroup (hepatitis B [HBV] or C [HCV] and Other). Pre-treatment serum HBV DNA and HCV RNA were quantified using Roche CO…

medicine.medical_specialtyCarcinoma Hepatocellular610 Medizin610 Medicine & healthChronic liver diseaseAntibodies Monoclonal HumanizedGastroenterologyRamucirumab03 medical and health sciencesLiver disease0302 clinical medicine610 Medical sciencesInternal medicineMedicineHumans030304 developmental biology0303 health sciencesHepatologybusiness.industryLiver NeoplasmsHepatitis CHepatitis Bmedicine.diseasedigestive system diseases3. Good healthClinical Trials Phase III as Topic030220 oncology & carcinogenesisHepatocellular carcinomaLiver functionbusinessViral load
researchProduct